Amplicon Advisors is a strategic partner for the bioeconomy. We accelerate biotech innovation by aligning science, industry, policy, and capital — enabling smarter, faster, more confident decisions across R&D, scale-up, regulation, and commercialization.
The word Amplicon comes from biology, where it describes a fragment of DNA that becomes amplified — multiplied until it is powerful enough to shape the behavior of a whole system.
This is the metaphor behind our work.
Biotechnology holds extraordinary promise, but only when the right ideas, decisions, and collaborations are amplified.
Amplicon exists to strengthen those signals: the strategies, partnerships, and narratives that turn breakthrough science into breakthroughs for society and the planet.
Science alone cannot change the world — it needs alignment, strategy, and trust to make it beyond the lab.
Dr. Nadine Bongaerts is a synthetic biologist and entrepreneur committed to ensuring that biotechnology fulfills its potential to improve human and planetary health.
Over the course of her scientific and entrepreneurial career, she has witnessed a recurring pattern: breakthrough ideas rarely fail because the science is insufficient — they fail because the surrounding system is not ready.
This insight has shaped her mission: to strengthen the strategic, regulatory, and relational foundations that allow transformative biotechnologies to scale responsibly.
She is the founder of Amplicon Advisors, a Paris-based consultancy supporting biotech organizations, investors, and institutions at the intersection of science, strategy, and ecosystem alignment.
Her work focuses on bridging the gaps between discovery and deployment — helping leaders make better decisions, build trust, and create the partnerships required for real-world impact.
Previously, as Chief Innovation Officer at cultivated meat company Gourmey, Dr. Bongaerts oversaw the transition from R&D to production and led the first-ever cultivated meat submission to the European Food Safety Authority (EFSA).
She earned her Ph.D. in synthetic biology at Université Paris Cité/INSERM, where she developed a novel antibiotic discovery platform published in Nature Communications, and she studied biotechnology at Delft University of Technology and Leiden University.
Beyond her scientific work, she co-founded Science Matters to train researchers in communicating complex science, and has played leading roles in shaping international deep-tech ecosystems through her work with Hello Tomorrow, France Deeptech, and iGEM.
As a faculty member at Singularity University, she challenges leaders across industries to rethink what is possible at the frontier of biotechnology.
1. Ecosystem Development & Stakeholder Engagement
Biotechnology is advanced by collaboration and strong ecosystems.
We identify and connect you with high-value partners — corporates, investors, institutions, early adopters — and help you build he coalitions, ecosystem initiatives, and cross-sector engagements that amplify your influence or accelerate adoption.
2. Strategy & Decision Support
Biotechnology succeeds when science, market, policy, and society move in sync. We help organizations design holistic strategies that integrate scientific and technological readiness with regulatory pathways, political context, ecosystem dynamics, and stakeholder expectations.
The result: better decisions, reduced risk, and clearer routes to scale.
3. Biotech Startup Scouting & Due Diligence
We support investors and corporates by identifying and evaluating high-potential biotechnology ventures.
Our due diligence extends beyond technology: we assess regulatory readiness, business model strength, IP strategy, public affairs exposure, team dynamics, and ecosystem fit.
This holistic lens reduces risk and helps you recognize opportunities early.
4. Narratives That Build Trust & Mobilize Stakeholders
Breakthrough innovations need more than data — they need clarity, credibility, and resonance.
We craft scientific narratives and communication strategies that translate complex ideas into stories that move people: investors, policymakers, partners, and the public.
Our goal is to help you build legitimacy, alignment, and enthusiasm around your vision.
5. IP Valorisation & Business Development
Many brilliant bioinnovations never make it beyond the bench.
We help innovators and institutions valorise scientific assets by identifying feasible applications, assessing technology–market fit, shaping viable commercial pathways, and building the strategic relationships required to move early-stage science toward real-world deployment.
Our work supports the translation of scientific potential into credible, compelling, and investable market value propositions.
